Libra Infusions Limited (DSE:LIBRAINFU)

Market Cap	1.42B -23.2%
Revenue (ttm)	197.03M -19.6%
Net Income	1.58M -68.2%
EPS	0.70 -68.2%
Shares Out	2.25M
PE Ratio	896.37
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,507
Average Volume	9,708
Open	626.10
Previous Close	630.30
Day's Range	625.40 - 639.00
52-Week Range	594.20 - 850.00
Beta	-0.49
RSI	40.62
Earnings Date	n/a

About Libra Infusions

Libra Infusions Limited manufactures and sells intravenous fluids in Bangladesh. Its products are used in medical situations, including diarrhoeal disease, surgical operation, loss of blood, weakness, and hospitalization. The company offers LIBOTT, LIBOTT-10, LIBOTT-25, LIBOTT-S, LIBOTT-S JR, NORMASOL, BABY SALINE, DIASOL, HARTSOL, LIBRAZOL, LIBRACIN, LIBOTT-M, LIBRACIN-400, and LIBRET products. The company was formerly known as Libra Pharmaceutical Limited and changed its name to Libra Infusions Limited in 1999. Libra Infusions Limited was inc...

• Industry: Pharmaceutical Preparations
• Founded: 1976
• Employees: 699
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: LIBRAINFU

Financial Performance

In fiscal year 2019, Libra Infusions's revenue was 197.03 million, an increase of 3.31% compared to the previous year's 190.72 million. Earnings were 1.58 million, a decrease of -72.49%.